Abstract
Introduction
In medullary thyroid carcinoma, there is currently no consensus about the prognostic value of histological and immunohistochemical parameters. This study was designed to analyze the value of various histological and immunohistochemical characteristics for predicting the recurrence of medullary carcinoma.
Methods
A total of 55 cases of medullary thyroid carcinoma have been reviewed. These were operated on consecutively between 1971 and 2004 after histological confirmation. The data referring to clinical characteristics and evolution were taken from the patient’s clinical history. The macroscopic, microscopic, and immunohistochemical characteristics of the tumors were taken from the pathological anatomy report.
Results
In 14 (27%) cases, there was recurrence of the disease. The disease-free interval at 1 year was 88 ± 5%; at 5 years 73 ± 7%; at 10 years 73 ± 7%; at 15 years 61 ± 10%; and at 20 years or more 61 ± 10%. Of the histological parameters, only vascular invasion (0.0098) was related to a higher relapse rate. No epidemiological variable or immunohistochemical marker was associated with relapse. However, it was found that staging (P = 0.0102), as well as tumor size (P = 0.0211) and lymph node affectation (P = 0.0012), are factors significantly related to relapse of the disease. According to Cox’s regression model, the only variable with a statistically significant effect was vascular invasion (P = 0.0056; odds ratio = 5.2308).
Conclusions
The overall recurrence rate was 27%, and the main independent prognostic factor of recurrence was tumoral vascular invasion at diagnosis. Staging, tumor size, and lymph node metastasis are prognostic factors of recurrence, although they are not significant in the multivariate analysis.
Similar content being viewed by others
References
Weber T, Schilling T, Buchler MW. Thyroid carcinoma. Curr Opin Oncol. 2006;18:30–5.
Ríos A, Rodríguez JM, Canteras M, Galindo PJ, Tebar FJ, Parrilla P. Surgical management of multinodular goiter with compression symptoms. Arch Surg. 2005;140:49–53
Ríos A, Rodríguez JM, Galindo PJ, Canteras M, Parrilla P. Surgical treatment for multinodular goitres in geriatric patients. Langenbeck Arch Surg. 2005;390:236–42
Ríos A, Rodríguez JM, Canteras M, Galindo PJ, Balsalobre MD, Soria T, Parrilla P. Risk factors for malignancy in multinodular goitres. Eur J Surg Oncol. 2004;30:58–62
Ball DW. Medullary thyroid cancer: monitoring and therapy. Endocrinol Metab Clin North Am. 2007;36:823–37.
Hoff AD. Medullary thyroid carcinoma. Hematol Oncol Clin North Am. 2007;21:475–88.
Kebebew E, Ituarte P, Siperstein A, Duh QY, Klark O. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison OS staging system. Cancer. 2000;88:1139–48.
Brierley JD, Tsang R, Simpson WJ, Gospodarowicz M, Sutcliffe S, Panzarella T. Medullary thyroid cancer: analyses of survival and prognostic factors and the role of radiation therapy in local control. Thyroid. 1996;6:305–10.
Franc B, Rosenberg Bourgin M, Caillou B, et al. Medullary thyroid carcinoma: search for histological predictors of survival (109 proband cases analysis). Hum Pathol. 1998;29:1078–84.
Modigliani E, Cohen R, Campos JM, Conte-Devolx D, Maes B, Boneu A, et al. Prognostic factor for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Clin Endocrinol. 1998;48:265–73.
Gulben K, Berberoglu U, Boyabatli M. Prognostic factors for sporadic medullary thyroid carcinoma. World J Surg. 2006;30:84–90.
Roman S, Lin R, Sosa JA. Prognosis of medullary thyroid carcinoma: demographic, clinical and pathologic predictors of survival in 1252 cases. Cancer. 2006;107:2134–42.
Clark JR, Fridman TR, Odell MJ, Brierley J, Walfish PG, Freeman JL. Prognostic variables and calcitonin in medullary thyroid cancer. Laryngoscope. 2005;115(8):1445–50.
Traugott A, Moley JF. Medullary thyroid cancer: medical management and follow-up. Curr Treat Options Oncol. 2005;6:339–46.
Helbling B, Wharton K, McLeod MK. Medullary thyroid cancer: the controversy continues. Curr Surg. 2004;61:537–45.
Albores J, Monforte H, Hadji M, Morales AR. C cell hyperplasia in thyroid tissue adjacent to follicular cell tumors. Hum Pathol. 1988;19:795–9.
Bergholm U, Adami HO, Auer G, Bergstrom R, Backdahl M, et al. Histopathological characteristics and DNA contents as prognostic factor in medullary thyroid carcinoma: a nationwide study in Sweden. Cancer. 1989;64:135–142.
Hermanek P, Sobin LH, editors. UICC TNM classfication of malignant tumours. 4th ed. Berlin: Springer Verlag; 1987.
Dottorini M, Assi A, Sironi M, Sangalli G, Spreafico G, Colombo L. Multivariate analysis of patients with medullary thyroid carcinoma. Prognostic significance and impact on treatment of clinical and pathological variables. Cancer. 1996;77:1556–65.
Fuchshuber PR, Loree TR, Hicks WL, Cheney RT, Shedd DP. Medullary carcinoma of the thyroid: prognostic factors and treatment recommendations. Ann Surg Oncol. 1998;5:81–6.
Samaan NA, Schultz PN, Hickey RC. Medullary thyroid carcinoma. Prognosis of familial versus sporadic disease and the role of radiotherapy. J Clin Endocrinol Metab. 1988;7:801–5.
Ukkat J, Gimm O, Brauckhoff M, Bilkenroth U, Dralle H. Single center experience in primary surgery for medullary thyroid carcinoma. World J Surg. 2004;28:1271–4.
Brauckhoff M, Lorenz K, Ukkat J, Brauckhoff K, Gimm O, Dralle H. Medullary thyroid carcinoma. Scand J Surg. 2004;93:249–60.
Gimm O, Ukkat J, Niederle BE, Weber T, Thanh PN, Brauckhoff M, Niederle B, Dralle H. Timing and extent of surgery in patients with familial medullary thyroid carcinoma/multiple endocrine neoplasia 2A-related RET mutations not affecting codon 634. World J Surg. 2004;28:1312–6.
Hyer SL, Vini L, A’Hern R, Harmer C. Medullary thyroid cancer: multivariate analyses of prognostic factors influencing survival. Eur J Surg Oncol. 2000;26:686–90.
Kakudo K, Carney JA, Sizemore GW. Medullary carcinoma of the thyroid. Biological behavior of the sporadic and familial neoplasm. Cancer. 1985;55:2818–21.
Saad MF, Ordonez NG, Rashid RK, Guido JJ, Hill CS Jr, Hickey RC, Samaan NA. Medullary carcinoma of the thyroid. A study of the clinical features and prognostic factors in 161 patients. Medicine (Baltimore). 1984;63:319–42.
Schröder S, Böcker W, Baisch H, et al. Prognostic factor in medullary thyroid carcinoma. Survival in relation to age, sex, stage, histology, immunocytochemistry and DNA content. Cancer. 1988;61:806–16.
Williams ED, Brown CL, Doniach I. Pathological and clinical findings in a series of 67 medullary carcinoma of the thyroid. J Clin Pathol. 1966;19:103–13.
Holm R, Sobrinho M, Nesland JM, Gould VE, Johanness JV. Medullary carcinoma of the thyroid gland: an immunocytochemical study. Ultrastruct Pathol. 1985;8:25–41.
Pyke CM, Hay ID, Goellner JR, Bergstrahl EJ, van Heerden JA, Grant CS. Prognostic significance of calcitonin immunoreactivity, amyloid staining, and flow cytometric DNA measurements in medullary thyroid carcinoma. Surgery. 1991;110:964–70.
Bergholm U, Bergstrom R, Ekbom A. Long-term follow-up of patients with medullary carcinoma of the thyroid. Cancer. 1997;79:132–8.
Fontanini G, Vignati S, Pacini F, Pollina L, Basolo F. Microvessel count: an indicator of poor outcome in medullary thyroid carcinoma but not in other types of thyroid carcinoma. Mod Pathol. 1996;9:634–41.
Bigner SH, Cox EB, Mendelsohn G, Baylin SB, Wells SA Jr, Eggleston JC. Medullary carcinoma of the thyroid in the multiple endocrine neoplasia 2A syndrome. Am J Surg Pathol. 1981;5:459–72.
Saad MF, Ordonez NG, Guido JJ, Samaan NA. The prognostic value of calcitonin immunostaining in medullary carcinoma of the thyroid. J Clin Endocrinol Metab. 1984;59:850–6.
Pacini F, Basolo F, Rossella E, Fugazzola L, Cola A, Pinchera A. Medullary thyroid cancer: an immunohistochemical and humoral study using six separate antigens. Am J Clin Pathol. 1991;95:300–8.
Pollina L, Pacini F, Fontanini G, Vignati S, Bevilacqua G, Basolo F. Bcl-2, p53 and proliferating cell nuclear antigen expression is related to the degree of differentiation in thyroid carcinomas. Br J Cancer. 1996;73:139–43.
Wang DG, Liu WH, Johnston CF, Sloan JM, Buchanan KD. Bcl-2 and c-Myc, but not bax and p53, are expressed during human medullary thyroid tumorogenesis. Am J Pathol. 1998;152:1407–13.
Viale G, Roncalli M, Grimelius L, et al. Prognostic value of bcl-2 immunoreactivity in medullary thyroid carcinoma. Hum Pathol. 1995;26:945–50.
Goldenberg JD, Portugal LG, Wenig BL, Ferrer K, Wu JC, Sabnani J. Well-differentiated thyroid carcinoma: p53 status and microvessel density. Head Neck. 1998;20:152–8.
Horii A, Yoshida J, Sakai M, Okamoto S, et al. Ki-67 positive fractions in benign and malignant thyroid tumours: application of flow cytometry. Acta Otolaryngol. 1999;119:617–20
Tisell LE, Oden A, Muth A, Altiparmak G, Molne J, Ahlman H, Nilsson O. The Ki67 index a prognostic marker in medullary thyroid carcinoma. Br J Cancer. 2003;89:2093–7.
Yokota J, Yamamoto T, Toyoshima K, et al. Amplification of the c-erb-B2 oncogene in human adenocarcinomas in vivo. Lancet. 1986;1:765–7.
Soda G, Antonaci A, Bosco D, Nardoni S, Melis M. Expression of bcl-2, c-erb-B2, p53, and p21 (wafl-cip1) protein in thyroid carcinoma. J Exp Clin Cancer Res. 1999;18:363–70.
Ito Y, Yoshida H, Motoo Y, Iovanna JL, Tomoda C, Uruno T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Kuma K, Miyauchi A. Expression of p8 protein in medullary thyroid carcinoma. Anticancer Res. 2005;25:3419–23.
Ito Y, Yoshida H, Tomoda C, Uruno T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Kuma K, Nakamura Y, Kakudo K, Miyauchi A. Expression of cdc25B and cdc25A in medullary thyroid carcinoma: cdc25B expression level predicts a poor prognosis. Cancer Lett. 2005;229:291–7.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ríos, A., Rodríguez, J.M., Acosta, J.M. et al. Prognostic Value of Histological and Immunohistochemical Characteristics for Predicting the Recurrence of Medullary Thyroid Carcinoma. Ann Surg Oncol 17, 2444–2451 (2010). https://doi.org/10.1245/s10434-010-1021-4
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-010-1021-4